Autism spectrum disorder: pathogenesis, biomarker, and intervention therapy
- PMID:38434761
- PMCID: PMC10908366
- DOI: 10.1002/mco2.497
Autism spectrum disorder: pathogenesis, biomarker, and intervention therapy
Abstract
Autism spectrum disorder (ASD) has become a common neurodevelopmental disorder. The heterogeneity of ASD poses great challenges for its research and clinical translation. On the basis of reviewing the heterogeneity of ASD, this review systematically summarized the current status and progress of pathogenesis, diagnostic markers, and interventions for ASD. We provided an overview of the ASD molecular mechanisms identified by multi-omics studies and convergent mechanism in different genetic backgrounds. The comorbidities, mechanisms associated with important physiological and metabolic abnormalities (i.e., inflammation, immunity, oxidative stress, and mitochondrial dysfunction), and gut microbial disorder in ASD were reviewed. The non-targeted omics and targeting studies of diagnostic markers for ASD were also reviewed. Moreover, we summarized the progress and methods of behavioral and educational interventions, intervention methods related to technological devices, and research on medical interventions and potential drug targets. This review highlighted the application of high-throughput omics methods in ASD research and emphasized the importance of seeking homogeneity from heterogeneity and exploring the convergence of disease mechanisms, biomarkers, and intervention approaches, and proposes that taking into account individuality and commonality may be the key to achieve accurate diagnosis and treatment of ASD.
Keywords: autism spectrum disorder; biomarker; intervention therapy; molecular mechanisms; multi‐omics.
© 2024 The Authors. MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.
Conflict of interest statement
All authors read and approved the final manuscript and declare they have no conflicts of interest.
Figures




Similar articles
- Biomarkers of mitochondrial dysfunction in autism spectrum disorder: A systematic review and meta-analysis.Frye RE, Rincon N, McCarty PJ, Brister D, Scheck AC, Rossignol DA.Frye RE, et al.Neurobiol Dis. 2024 Jul;197:106520. doi: 10.1016/j.nbd.2024.106520. Epub 2024 May 3.Neurobiol Dis. 2024.PMID:38703861
- A study of genetic heterogeneity in autism spectrum disorders based on plasma proteomic and metabolomic analysis: multiomics study of autism heterogeneity.Tang X, Feng C, Zhao Y, Zhang H, Gao Y, Cao X, Hong Q, Lin J, Zhuang H, Feng Y, Wang H, Shen L.Tang X, et al.MedComm (2020). 2023 Sep 24;4(5):e380. doi: 10.1002/mco2.380. eCollection 2023 Oct.MedComm (2020). 2023.PMID:37752942Free PMC article.
- Paving the Way toward Personalized Medicine: Current Advances and Challenges in Multi-OMICS Approach in Autism Spectrum Disorder for Biomarkers Discovery and Patient Stratification.Mesleh AG, Abdulla SA, El-Agnaf O.Mesleh AG, et al.J Pers Med. 2021 Jan 13;11(1):41. doi: 10.3390/jpm11010041.J Pers Med. 2021.PMID:33450950Free PMC article.Review.
- Oxidative Stress in Autism Spectrum Disorder-Current Progress of Mechanisms and Biomarkers.Liu X, Lin J, Zhang H, Khan NU, Zhang J, Tang X, Cao X, Shen L.Liu X, et al.Front Psychiatry. 2022 Mar 1;13:813304. doi: 10.3389/fpsyt.2022.813304. eCollection 2022.Front Psychiatry. 2022.PMID:35299821Free PMC article.Review.
- Autism Spectrum Disorder: Neurodevelopmental Risk Factors, Biological Mechanism, and Precision Therapy.Wang L, Wang B, Wu C, Wang J, Sun M.Wang L, et al.Int J Mol Sci. 2023 Jan 17;24(3):1819. doi: 10.3390/ijms24031819.Int J Mol Sci. 2023.PMID:36768153Free PMC article.Review.
Cited by
- Environmental pollutants as risk factors for autism spectrum disorders: a systematic review and meta-analysis of cohort studies.Duque-Cartagena T, Dalla MDB, Mundstock E, Neto FK, Espinoza SAR, de Moura SK, Zanirati G, Padoin AV, Jimenez JGP, Stein AT, Cañon-Montañez W, Mattiello R.Duque-Cartagena T, et al.BMC Public Health. 2024 Sep 3;24(1):2388. doi: 10.1186/s12889-024-19742-w.BMC Public Health. 2024.PMID:39223561Free PMC article.
- Roles of Epigenetics and Glial Cells in Drug-Induced Autism Spectrum Disorder.Csoka AB, El Kouhen N, Bennani S, Getachew B, Aschner M, Tizabi Y.Csoka AB, et al.Biomolecules. 2024 Apr 3;14(4):437. doi: 10.3390/biom14040437.Biomolecules. 2024.PMID:38672454Free PMC article.Review.
References
- Kanner L. Autistic disturbances of affective contact. Acta Paedopsychiatr. 1968;35(4):100‐136. - PubMed
- Asperger H. Die “Autistischen psychopathen” im kindesalter. Arch Psychiat Nervenkrankheiten. 1944;117(1):76‐136.
- Wing L, Gould J. Systematic recording of behaviors and skills of retarded and psychotic children. J Autism Child Schizophr. 1978;8(1):79‐97. - PubMed
- APA . Diagnostic and Statistical Manual of Mental Disorders. American Psychiatric Association; 2013.
- Fombonne E. Editorial: the rising prevalence of autism. J Child Psychol Psychiatry. 2018;59(7):717‐720. - PubMed
Publication types
Related information
LinkOut - more resources
Full Text Sources